Share-based Payment Arrangement, Expense of Immunome Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Immunome Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Immunome Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $6,747,000, a 38% increase year-over-year.
  • Immunome Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $23,267,000, a 77% increase year-over-year.
  • Immunome Inc. annual Share-based Payment Arrangement, Expense for 2024 was $15,748,000, a 153% increase from 2023.
  • Immunome Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,223,000, a 17% increase from 2022.
  • Immunome Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,332,000, a 55% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Immunome Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $23,267,000 $6,747,000 +$1,855,000 +38% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $21,412,000 $5,347,000 +$2,120,000 +66% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $19,292,000 $5,703,000 +$3,544,000 +164% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $15,748,000 $5,470,000 +$2,587,000 +90% 01 Oct 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
Q3 2024 $13,161,000 $4,892,000 +$3,809,000 +352% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $9,352,000 $3,227,000 +$2,194,000 +212% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $7,158,000 $2,159,000 +$935,000 +76% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $6,223,000 $2,883,000 +$1,528,000 +113% 01 Oct 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
Q3 2023 $4,695,000 $1,083,000 -$257,000 -19% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $4,952,000 $1,033,000 -$294,000 -22% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $5,246,000 $1,224,000 -$86,000 -6.6% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $5,332,000 $1,355,000 +$136,000 +11% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $5,196,000 $1,340,000 +$185,000 +16% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $5,011,000 $1,327,000 +$578,000 +77% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $4,433,000 $1,310,000 +$985,000 +303% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $3,448,000 $1,219,000 +$1,583,000 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $1,865,000 $1,155,000 +$355,000 +44% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $1,510,000 $749,000 +$710,000 +1821% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $800,000 $325,000 +$179,000 +123% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $621,000 $364,000 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $800,000 +$799,000 01 Sep 2020 30 Sep 2020 10-Q 16 Nov 2020 2020 Q3
Q3 2020 $117,000 +$116,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $39,000 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $146,000 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q3 2019 $1,000* 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3

Immunome Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $15,748,000 +$9,525,000 +153% 01 Jan 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
2023 $6,223,000 +$891,000 +17% 01 Jan 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
2022 $5,332,000 +$1,884,000 +55% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $3,448,000 +$2,827,000 +455% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $621,000 +$607,000 +4336% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2019 $14,000 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.